Oramed Pharmaceuticals Opposes Nano Dimension's $890M Acquisition, Increases Stake to 7.2%
NNDM is trading near its 52-week low of $1.19 (12% above the low) on elevated volume (2.4× avg).
Summary
Significant shareholder Oramed Pharmaceuticals has increased its stake to 7.2% and is strongly opposing Nano Dimension's proposed $890 million acquisition, signaling a major corporate battle.
Key Events · Ownership and Investor Activity · NNDM
-
Increased Stake
Oramed Pharmaceuticals Inc. increased its beneficial ownership to 7.2% of Nano Dimension's ordinary shares, totaling 15,079,708 shares.
-
Significant Share Purchases
Oramed spent approximately $8.7 million to acquire 6,336,565 shares in open market purchases between May 13 and June 15, 2026.
-
Opposition to Acquisition
Oramed Pharmaceuticals stated its strong opposition to Nano Dimension's proposed $890 million acquisition of Infinite Epigenetics, believing it is not in shareholders' best interests. This follows Nano Dimension's announcement of the acquisition on June 15, 2026.
-
Ongoing Activist Battle
This opposition adds to existing corporate governance challenges, including an ongoing activist campaign by Murchinson Ltd., creating further uncertainty regarding the company's strategic direction.
Analysis · NNDM · Manufacturing
Oramed Pharmaceuticals, a significant shareholder, has publicly declared its strong opposition to Nano Dimension's recently announced $890 million acquisition of Infinite Epigenetics. This opposition comes after Oramed significantly increased its stake by purchasing over $8.7 million in shares, bringing its total ownership to 7.2%. This sets the stage for a major corporate governance battle over the company's strategic direction, especially given the ongoing activist pressure from Murchinson Ltd. The market typically reacts negatively to such uncertainty and internal conflict.
At the time of this filing, NNDM was trading at $1.33 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $255.8M. The 52-week trading range was $1.19 to $2.32. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.